阿仑膦酸钠治疗老年糖尿病合并骨质疏松的临床效果

Clinical efficacy of alendronate in treatment of elderly diabetic patients complicated with osteoporosis

摘要:

目的 观察阿仑膦酸钠治疗老年糖尿病合并骨质疏松的临床效果。方法 选取2017年6月至2018年12月期间我院收治的100例糖尿病合并骨质疏松的老年患者作为研究对象,根据入院的奇偶顺序分别纳入对照组和治疗组,各50例。对照组给予常规方法治疗,治疗组在对照组的基础上给予口服阿仑膦酸钠治疗。两组均治疗3个月。比较2组患者治疗前后骨代谢标志物Ⅰ型胶原交联氨基端肽(NTXI)、Ⅰ型胶原交联羧基端肽(CTXI)、抗酒石酸酸性磷酸酶5b(TRACP5b)和血骨钙素(BGP)、骨密度(BMD)和骨碱性磷酸酶(BALP)等,并比较2组患者临床治疗效果。采用SPSS 18.0软件对数据进行统计学分析。结果 治疗组的总有效率明显高于对照组,差异具有统计学意义(92.0%和64.0%, P<0.05)。治疗前两组患者的NTXI、CTXI、TRACP5b、BGP、BMD和BALP等水平差异均无统计学意义(P>0.05)。治疗后,2组NTXI、CTXI、TRACP5b、BGP和BALP水平均显著低于治疗前,且治疗组显著低于对照组[NTXI:(32.22±5.45)和(43.02±5.74)nmol/L；CTXI:(178.36±16.43)和(208.34±19.22)ng/L；TRACP5b:(3.10±0.81)和(3.86±0.85)ng/L; BGP:(2.16±0.46)和(5.44±1.37)μg/L及BALP:(237.33±18.28)和(270.43±21.12)U/L],差异均有统计学意义(P<0.01)。治疗后,2组BMD均显著高于治疗前,且治疗组显著高于对照组[(0.97±0.17)和(0.82±0.13)g/cm²],差异具有统计学意义(P<0.01)。结论 阿仑膦酸钠治疗老年糖尿病合并骨质疏松的临床效果显著,值得临床推广。

Abstract:

Objective To observe the clinical effect of alendronate sodium in the treatment of senile diabetes mellitus complicated with osteoporosis. Methods A total of 100 elderly diabetes mellitus patients complicated with senile osteoporosis admitted in our hospital from June 2017 to December 2018 were recruited in this study, and according to the parity order of their hospitalized admision, they were assigned into control group and treatment group, with 50 cases in each group. The control group were given conventional treatment, and the treatment group were given same treatment and oral administration of alendronate sodium phosphonic acid for 3 months. Bone metabolism markers, type Ⅰ collagen cross-linked aminoterminus peptide (NTXI), type Ⅰ collagen cross-linked carboxyl terminus peptide (CTXI), anti-tartaric acid phosphatase 5b (TRACP5b), blood osteocalcin (BGP), and bone alkaline phosphatase (BALP) and bone mineral density (BMD) were detected in the 2 groups before and after treatment to compare the clinical treatment effect. SPSS statistics 18.0 was used for data analysis. Results The overall response rate was significantly higher in the treatment group than in the control group (92.0% vs 64.0%, P<0.05). There were no significant differences in NTXI, CTXI, TRACP5b, BGP, BMD and BALP between the 2 groups before treatment (P>0.05), and the levels were significantly decreased after the treatment, with those in the treatment group lower than those of the control group [(NTXI:(32.22±5.45) vs (43.02±5.74)nmol/L, CTXI:(178.36±16.43) vs (208.34±19.22)ng/L, TRACP5b:(3.10±0.81) vs (3.86±0.85)ng/L, BGP:(2.16±0.46) vs (5.44±1.37)μg/L, BALP:(237.33±18.28) vs (270.43±21.12)U/L, all P<0.01]. The BMD was increased in both group, and that in the treatment group [(0.97±0.17)g/cm²] was significantly higher than that of the control group [(0.82±0.13)g/cm², P<0.01]. Conclusion Alendronate sodium is of significant efficacy in the treatment of senile diabetes mellitus combined with osteoporosis, and is worthy of clinical promotion.